logo
Plus   Neg
Share
Email

AstraZeneca: Phase III NEPTUNE Trial Of Imfinzi Fails To Meet Primary Goal

AstraZeneca plc (AZN.L,AZN) announced Wednesday final overall survival or OS results from the Phase III NEPTUNE trial of Imfinzi plus tremelimumab in Stage IV non-small cell lung cancer or NSCLC.

In the trial, the combination of Imfinzi and tremelimumab did not meet the primary endpoint of improving OS, while safety and tolerability profile for the combination was consistent with previous trials.

The Phase III NEPTUNE trial was a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) in combination with tremelimumab, an anti-CTLA4 antibody, vs. standard-of-care or SoC platinum-based chemotherapy in previously-untreated Stage IV (metastatic) NSCLC patients.

The trial is being conducted in more than 200 centres across 29 countries, including the US, Europe, South and Central America, the Middle East and Asia.

The company noted that the trial was performed in an all-comers population. The primary analysis population was patients with a high tumour mutational burden or TMB, which is a measurement of the number of mutations within the genome of a tumour.

According to the company, in the primary analysis population of patients whose blood TMB was 20 or more mutations per megabase or mut/Mb, the combination of Imfinzi and tremelimumab did not meet the primary endpoint of improving OS compared to SoC chemotherapy.

José Baselga, Executive Vice President, Oncology R&D said, "We are fully committed to a deep analysis of the vast clinical and biomarker data from this trial to gain further insights to improve Immuno-Oncology approaches for patients with metastatic non-small cell lung cancer."

AstraZeneca plans to submit the full results for presentation at a forthcoming medical meeting.

Imfinzi is also being tested as monotherapy in the Phase III PEARL trial, and in combination with chemotherapy with or without tremelimumab in the Phase III POSEIDON trial. These are part of an extensive late-stage Immuno-Oncology programme in Stage IV NSCLC.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lowe's Companies Inc. (LOW) and Office Depot Inc. (ODP) reported profit for their fourth-quarter, while TJX Companies' (TJX) profit increased 17 percent from the prior year. TJX plans to increase dividend by 13 percent and to buy back up to $2.25 billion of stock. Starbucks is introducing plant-based meat to its menu in Canada in early March. The Seattle-based coffee chain said it will introduce a new Beyond Meat, Cheddar and Egg Sandwich to its Canadian stores on March 3, along with the launch of its new spring menu. The meatless breakfast sandwich will be part of Starbucks Canada's core menu. Auto major Ford Motor Co. issued a safety compliance recall for a total of 217,185 F-150 pickup trucks with LED headlamps in North America, including 50,989 in Canada, to fix issues with the headlamps that could increase risk of a crash. The F-150 has been the top selling U.S. vehicle by any manufacturer for more than 40 years.
Follow RTT
>